SCHEMBL9540067

SCHEMBL9540067

C=CCC1(c2ccco2)c2cc(Cl)ccc2NC(=O)N1C

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 5/20 0.45
PGR P06401 7/20 0.39
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
RPS6KA3 P51812 1/20 0.36
IDO1 P14902 2/20 0.34
NR3C2 P08235 2/20 0.34
AR P10275 2/20 0.34
PDE7A Q13946 1/20 0.32
TSHR P16473 1/20 0.32
CBX7 O95931 1/20 0.32
CDYL2 Q8N8U2 1/20 0.32
CDYL Q9Y232 1/20 0.32
CDY1; CDY1B Q9Y6F8 1/20 0.32
NR3C1 P04150 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9539139 0.76 PDE7A (0.43) AKR1B1PGRCHRNB2CHRNA4RPS6KA3
SCHEMBL9540131 0.74 AKR1B1 (0.44) AKR1B1PGRRPS6KA3IDO1NR3C2
SCHEMBL9539026 0.74 PTGDR2 (0.43) CHRNB2CHRNA4
SCHEMBL9539975 0.71 AKR1B1 (0.49) AKR1B1PGRIDO1PDE7ACBX7
SCHEMBL9538999 0.71 AKR1B1 (0.49) AKR1B1PGRIDO1PDE7ATSHR
SCHEMBL9540123 0.70 PGR (0.43) AKR1B1PGRIDO1
SCHEMBL9539722 0.70 AKR1B1 (0.50) AKR1B1PGRIDO1TSHRHTR7
SCHEMBL9539047 0.69 AKR1B1 (0.48) AKR1B1PGRIDO1HTR7
SCHEMBL2471238 0.67 MAPT (0.36) AKR1B1PGRIDO1HTR7
SCHEMBL9540109 0.66 TP53 (0.43) CBX7CDYL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0530994-A1 Quinazoline derivatives as inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1993-03-10 EP disclosed
WO-1993004047-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE MERCK & CO., INC. (US) 1993-03-04 WO disclosed